Photinia Biosciences key facts
as of Oct 2026- Operator of a radiopharmaceutical company intended to selectively target cancer cells and enable deep tumor penetration.
- Photinia Biosciences is valued at approximately $14.0M as of Oct 2026 (last reported valuation).
- It has raised $6.6M; the latest was Seed Round ($6.6M) in Sep 2025.
- Notable investors include Red Tree Venture Capital.
- Status: Privately Held (backing).
Last reported valuation
LOW confidence$14.0M
Photinia Biosciences's last reported valuation, Sep 2025. Nothing priced has surfaced since.
Free account
More of Photinia Biosciences with a free account
- ·Watch Photinia Biosciences: the Monday email on marks, rounds and moves
Photinia Biosciences funding rounds
No rounds on record
No funding rounds for Photinia Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Pro members can request priority coverage with a 48-hour turnaround.
Who backs Photinia Biosciences
1Photinia Biosciences valuation
Photinia Biosciences's last reported valuation was $14 million in Sep 2025. No priced round, secondary trade or fund mark has surfaced since.
Photinia Biosciences investors
1 investor is on record for Photinia Biosciences, including Red Tree Venture Capital. By type, the record holds 1 venture capital firm.
About Photinia Biosciences
Operator of a radiopharmaceutical company intended to selectively target cancer cells and enable deep tumor penetration.
- Sector
- Healthcare
- HQ
- Redwood City, CA, United States
- Founded
- 2024
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.